BioScience Trends. 2014;8(6):339-345. (DOI: 10.5582/bst.2014.01101)

Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients.

Kaneko J, Sugawara Y, Yamaguchi T, Harada N, Akamatsu N, Ishizawa T, Aoki T, Sakamoto Y, Hasegawa K, Tamura S, Tanaka T, Kokudo N


SUMMARY

Telaprevir (TVR), a direct -acting protease inhibitor, was recently reported to improve treatment efficacy when used in combination with peg-interferon (PEG-IFN) and ribavirin (RBV) as triple therapy for HCV in non-transplant patients. The aim of the present study was to investigate the feasibility of TVR-based triple therapy among Japanese living donor liver transplant (LDLT) recipients who had been resistant to dual treatment with PEG-IFN and RBV. Among 133 HCV-positive LDLT recipients, 8 null responders during or after dual treatment with PEG-IFN and RBV were finally indicated for TVR-based triple therapy after treatment. All 8 patients had been resistant to dual treatment with PEG-IFN and RBV. While the cyclosporine trough level was well controlled with an 80% dose reduction during TVR administration, the end - of - treatment response rate was only 25% (2/8), with 63% (5/8) of patients developing anemia that required a blood transfusion and 50% (4/8) of patients developing leukopenia that required filgrastim. Dose reduction or treatment discontinuation was required in all cases. Based on the poor efficacy and the unacceptable high rate of cytopenic events, TVR-based triple therapy is not indicated for those resistant to dual treatment with PEG-IFN and RBV.


KEYWORDS: Hepatitis C, Telaprevir, living donor liver transplantation, Japanese, null responder

Full Text: